journal
Journals International Journal of Gynec...

International Journal of Gynecological Cancer

https://read.qxmd.com/read/38925662/adjuvant-external-beam-radiotherapy-combined-with-brachytherapy-for-intermediate-risk-cervical-cancer
#21
JOURNAL ARTICLE
Nuria Agusti, David Viveros-Carreño, Alexander Melamed, Rene Pareja, Alexa Kanbergs, Chi-Fang Wu, Roni Nitecki, Lauren Colbert, Jose Alejandro Rauh-Hain
OBJECTIVE: Patients with intermediate-risk cervical cancer receive external beam radiotherapy (EBRT) as adjuvant treatment. It is commonly administered with brachytherapy without proven benefits. Therefore, we evaluated the frequency of brachytherapy use, the doses for EBRT administered alone or with brachytherapy, and the overall survival impact of brachytherapy in patients with intermediate-risk, early-stage cervical cancer. METHODS: This retrospective cohort study was performed using data collected from the National Cancer Database...
June 25, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38909994/apollo-neo-adjuvant-pembrolizumab-for-primary-vulvar-squamous-cell-carcinoma-a-multicenter-single-arm-phase-ii-clinical-proof-of-concept-study
#22
JOURNAL ARTICLE
M I E van Poelgeest, Kim E Kortekaas, Helena C van Doorn, Maaike Oonk, Hans W Nijman, Ingrid Boere, Anneke L Eerkens, Ann Reyners, Patricia C Ewing-Graham, Joost Bart, Tjalling Bosse, Marij J P Welters, Judith R Kroep, Sjoerd H van der Burg
BACKGROUND: Vulvar squamous cell carcinoma (VSCC) is a rare cancer for which the cornerstone of treatment is surgery with high complication rates. The unmet need is a less radical and more effective treatment for VSCC. PRIMARY OBJECTIVES: To investigate the impact of mono-immunotherapy pembrolizumab as neoadjuvant treatment for primary resectable VSCC patients. STUDY HYPOTHESIS: Some primary VSCC patients display a specific immune profile which is associated with better survival...
June 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38909993/prophylactic-mesh-to-prevent-incisional-hernia-in-laparotomy-for-ovarian-tumors
#23
JOURNAL ARTICLE
Berta Fabregó, Ester Miralpeix, Josep-Maria Sole-Sedeno, José-Antonio Pereira, Gemma Mancebo
OBJECTIVE: Incisional hernias are a common complication of midline laparotomies. The aim of this study was to determine the impact of prophylactic mesh placement after midline laparotomy for ovarian tumors on the incidence of incisional hernia. METHODS: We collected retrospective data from patients undergoing midline laparotomy for borderline or ovarian cancer with at least 12 months of follow-up, including those with and without mesh. Patient demographics, preoperative characteristics and risk factors for hernia were reported and grouped according to prophylactic mesh placement...
June 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38909992/considerations-for-route-of-hysterectomy-in-low-risk-cervical-cancer
#24
JOURNAL ARTICLE
X Mona Guo, Lynda D Roman, Koji Matsuo
No abstract text is available yet for this article.
June 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38909991/the-international-gynecologic-cancer-society-consensus-statement-on-palliative-care
#25
JOURNAL ARTICLE
Keiichi Fujiwara, Stephen R Connor, Noriko Fujiwara, Raimundo Correa, Anisa Mburu, Debbie Leopold, Mary Eiken, Michael Loran Pearl
At the International Gynecologic Cancer Society (IGCS) Global Meeting in 2023 held in Seoul, South Korea, we held a Presidential Plenary Session focusing on palliative care (https://www.youtube.com/watch?v=TBDIoQ50xgI). We hereby reaffirm the significance of this session, express the Palliative Care Declaration made by the IGCS, and describe our action plan for the future.
June 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38901970/immune-checkpoint-inhibitor-combinations-for-patients-with-advanced-endometrial-cancer-a-network-meta-analysis-and-cost-utility-analysis
#26
JOURNAL ARTICLE
Youwen Zhu, Kun Liu, Hong Zhu
BACKGROUND: Immune checkpoint inhibitor combinations show significant survival advantages compared with chemotherapy for patients with advanced endometrial cancer. OBJECTIVE: To compare the efficacy, safety, and cost-effectiveness of different immunotherapy combinations for clinician and patient decision-making. METHODS: The PubMed, Embase, Cochrane, and Web of Science Databases were reviewed from January 1, 2010 to October 30, 2023, for phase III randomized controlled trials of first-line immunotherapy combinations in patients with advanced endometrial cancer...
June 20, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876788/utilization-of-artificial-intelligence-to-mitigate-health-inequalities-in-gynecological-cancer-care
#27
JOURNAL ARTICLE
Laila Afroze, Md Sazedur Rahman
No abstract text is available yet for this article.
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876787/optimizing-patient-selection-for-secondary-cytoreductive-surgery-in-recurrent-endometrial-cancer
#28
JOURNAL ARTICLE
Virginia Vargiu, Andrea Rosati, Lucia Tortorella, Diana Giannarelli, Vito Andrea Capozzi, Valerio Gallotta, Alessandro Gioè, Ettore Di Stefano, Martina Corrado, Roberto Berretta, Francesco Cosentino, Giovanni Scambia, Francesco Fanfani
OBJECTIVE: This retrospective, multicenter, observational study aimed to refine patient selection criteria for secondary cytoreductive surgery in recurrent endometrial cancer. The objective was to identify preoperative predictors of complete cytoreduction, assess surgical complexity, and propose a preoperative predictive scoring system to identify suitable candidates for secondary cytoreductive surgery. METHODS: Data from 331 women with recurrent endometrial cancer were analyzed across three Italian centers from January 2010 to December 2021...
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876786/surgical-site-infection-prevention-bundle-in-gynecology-oncology-surgery-a-key-element-in-the-implementation-of-an-enhanced-recovery-after-surgery-eras-program
#29
REVIEW
Lucia Ribero, María Clara Santía, Kathleen Borchardt, Firaz Zabaneh, Amanda Beck, Archana Sadhu, Karen Edwards, Monica Harrelson, Aimee Pinales-Rodriguez, Elise Mann Yates, Pedro T Ramirez
Surgical site infection rates are among 5-35% in all gynecologic oncology procedures. Such infections lead to increased patient morbidity, reduction in quality of life, higher likelihood of readmissions, and reinterventions, which contribute directly to mortality and increase in health-related costs. Some of these are potentially preventable by applying evidence-based strategies in the peri-operative patient setting. The objective of this review is to provide recommendations for the individual components that most commonly comprise the surgical site infection prevention bundles that could be implemented in gynecologic oncology procedures...
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876785/operative-performance-indicators-benchmarking-gynecological-robotic-surgery
#30
JOURNAL ARTICLE
Faiza Gaba, Thomas Edward Ind, Marielle Nobbenhuis
No abstract text is available yet for this article.
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38862154/investigating-age-and-ethnicity-as-novel-high-risk-phenotypes-in-mucinous-ovarian-cancer-retrospective-study-in-a-multi-ethnic-population
#31
JOURNAL ARTICLE
Tejumola Olaoye, Ayushi -, William Boyle, Anthony Williams, Raji Ganesan, Kamana Subba, Akanksha Goyal, Elaine Leung, Rahul Chowdhary, Jennifer Pascoe, Sarah Williams, Jason Yap, Janos Balega, Satyam Kumar, Kavita Singh, Sudha S Sundar
OBJECTIVES: Primary mucinous ovarian carcinoma represents 3% of ovarian cancers and is typically diagnosed early, yielding favorable outcomes. This study aims to identify risk factors, focussing on the impact of age and ethnicity on survival from primary mucinous ovarian cancer. METHODS: A retrospective observational study of patients treated at Sandwell and West Birmingham Hospitals NHS Trust and University Hospital Coventry and Warwickshire. Patients included were women aged ≥16 years, with primary mucinous ovarian cancer confirmed by specialist gynecological histopathologist and tumor immunohistochemistry, including cytokeratin-7, cytokeratin-20, and CDX2...
June 11, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858106/a-non-comparative-randomized-phase-ii-trial-of-atezolizumab-or-atezolizumab-plus-tiragolumab-for-programmed-death-ligand-1-positive-recurrent-cervical-cancer-skyscraper-04
#32
JOURNAL ARTICLE
Ritu Salani, Mary McCormack, Yong-Man Kim, Sharad Ghamande, Shaundra L Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adrian Guzman Ramirez, Chien-Hsing Lu, Renaud Sabatier, Nicoletta Colombo, Youyou Hu, Venkatesh Krishnan, Luciana Molinero, Yuning Feng, Nicole Kim, Marcela Castro, Yvonne G Lin, Bradley J Monk
OBJECTIVE: To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer. METHODS: In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients with PD-L1-positive (SP263 tumor area positivity ≥5%) recurrent/persistent cervical cancer after 1-2 chemotherapy lines (≥1 platinum-based) were randomized 3:1 to atezolizumab 1200 mg with/without tiragolumab 600 mg every 3 weeks until disease progression or unacceptable toxicity...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858105/effects-of-niraparib-dose-reduction-on-short-term-outcomes-in-ovarian-cancer-patients
#33
JOURNAL ARTICLE
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, Carolina Maria Sassu, Sara Lardino, Camilla Culcasi, Domenica Lorusso, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
OBJECTIVES: Despite the individualized starting dose for maintenance therapy in ovarian cancer, the niraparib dose reduction rate remains high. The aim of this study was to evaluate the impact of niraparib dose reduction on progression-free survival in newly diagnosed primary advanced ovarian cancer and recurrent ovarian cancer patients. We also aimed to compare the reduction rates and the safety of niraparib on primary and relapse groups, and identify which factors may predict dose reduction...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858104/notable-surgical-trials-in-gynecologic-oncology-a-10-year-overview
#34
REVIEW
José C Vilches, María Clara Santía, Elise Mann Yates, Rene Pareja, Manuel Lozano, Pedro T Ramirez
In the last decade, we have witnessed important advances in novel therapeutics in the management of gynecologic cancers. These studies have built on the findings from preexisting data and have provided incremental contributions leading to changes that have not only impacted the accuracy of cancer detection and its metastatic components but also led to improvements in oncologic outcomes and quality of life. Key landmark trials have changed the standard of care in cervix, uterine, and ovarian cancer. A number of these have been controversial and have generated significant debate among gynecologic oncologists...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858103/mirvetuximab-soravtansine-in-folate-receptor-alpha-fr%C3%AE-high-platinum-resistant-ovarian-cancer-final-overall-survival-and-post-hoc-sequence-of-therapy-subgroup-results-from-the-soraya-trial
#35
JOURNAL ARTICLE
Robert L Coleman, Domenica Lorusso, Ana Oaknin, Sabrina Chiara Cecere, Hannelore Denys, Nicoletta Colombo, Toon van Gorp, Jason A Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Yuemei Wang, Brooke Esteves, Michael Method, Ursula Matulonis
OBJECTIVE: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate of 32.4% (95% CI, 23.6 to 42.2). Here we report final SORAYA trial results for overall survival and post hoc objective response rates in subgroups by sequence and number of prior therapies. METHODS: Eligible patients had high-grade serous platinum-resistant ovarian cancer with high FRα expression and one to three prior therapies (prior bevacizumab required)...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851241/response-to-correspondence-on-medicolegal-infrastructural-and-financial-aspects-in-gynecologic-cancer-surgery-and-their-implications-in-decision-making-processes-quo-vadis-by-nevin-and-bolton
#36
LETTER
Emma Allanson, Paul A Cohen, Robert Bristow
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851240/systematic-lymphadenectomy-and-interval-debulking-surgery-less-is-more
#37
EDITORIAL
Francesco Fanfani, Marco D'Indinosante
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851239/patterns-of-use-of-primary-and-first-line-chemotherapy-for-recurrence-among-patients-with-cervical-cancer
#38
JOURNAL ARTICLE
Alexandra Diggs, Yongmei Huang, Alexander Melamed, Elizabeh Szamreta, Matthew Joseph Monberg, Dawn Hershman, Jason D Wright
BACKGROUND: Little is known about real-world patterns of chemotherapy use in patients with cervical cancer. OBJECTIVE: To examine the patterns of chemotherapy use in patients with cervical cancer METHODS: We identified patients with cervical cancer in the IBM MarketScan Database who underwent primary hysterectomy or radiation therapy between 2011 and 2020 and described their treatment in the primary setting and at first recurrence. RESULTS: We identified 5390 patients: 2667 (49...
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851238/correspondence-on-medicolegal-infrastructural-and-financial-aspects-in-gynecologic-cancer-surgery-and-their-implications-in-decision-making-processes-quo-vadis-by-allanson-et-al
#39
LETTER
James Nevin, Helen Bolton
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38839421/impact-of-adjuvant-treatments-and-risk-factors-on-survival-in-2023-figo-stage-iib-endometrial-cancer-patients-turkish-gynecologic-oncology-group-study
#40
JOURNAL ARTICLE
Utku Akgör, Derman Basaran, Mehmet Mutlu Meydanli, Esra Kuscu, Fuat Demirkiran, Samet Topuz, Muzaffer Sancı, Ozgur Akbayır, Murat Gultekin, Mehmet Yavuz Salihoglu, Huseyin Akilli, Tugan Bese, Zeliha Fırat, Hamdullah Sozen, Nejat Ozgul, Ali Ayhan
OBJECTIVE: The aim of this study was to investigate the impact of adjuvant treatments, factors influencing recurrence, and survival data in patients with 2023 International Federation of Gynecology and Obstetrics (FIGO) stage IIB endometrial cancer. METHODS: A retrospective analysis was conducted on patients with endometrial cancer who underwent surgery between 2005 and 2022 at seven different centers in Turkey. Demographic, clinicopathological, and survival data were collected and analyzed...
June 5, 2024: International Journal of Gynecological Cancer
journal
journal
30825
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.